Why did MAIA's EPS remain flat in recent quarters?

The EPS of MAIA has remained flat in recent quarters due to a combination of factors:

1. Revenue Recognition: MAIA has been recognizing revenue from its collaboration with Regeneron for the development of cemiplimab, which has been a significant contributor to its revenue. This collaboration has provided a steady stream of income, helping to offset the costs of operating as a clinical-stage biotechnology company.
2. Cost Management: Despite the lack of profitability in recent quarters, MAIA has shown strategic financial management. For instance, the company's director, Steven Chaouki, has recently purchased additional shares in the company, indicating confidence in its long-term potential. This internal investment can be seen as a vote of confidence in the company's future financial health and the potential for growth in the biotechnology sector.

In conclusion, the flat EPS of MAIA can be attributed to a combination of factors, including revenue recognition from collaborations and effective cost management strategies. These factors, along with the company's ongoing clinical trials and potential for future profitability, suggest a promising outlook for MAIA Biotechnology.